Profile data is unavailable for this security.
About the company
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd is a China-based company mainly engaged in the research and development, production and sales of pharmaceuticals. The pharmaceutical research and development, production and sales business mainly engages in the research and development, production and sales of amoxicillin clavulanate potassium tablets, Liuwei Dihuang oral liquid, Heche Dazao capsules, Yangyin Qingfei syrup, menthol and mint oil. The pharmaceutical distribution business mainly engages in the wholesales of Chinese medicinal materials, Chinese herbal medicines, Chinese herbal formulas and fresh herbs, as well as the provision of medical services such as decoction, delivery, slicing, and powdering. The medical technology training and equipment sales service business includes medical technology education and training service business and medical equipment sales business. The big health business engages in the production and sales of big health and peripheral products.
- Revenue in CNY (TTM)251.56m
- Net income in CNY33.15m
- Incorporated1992
- Employees362.00
- LocationHangzhou TianMuShan Pharmaceutical Enterprise Co LtdRoom 1803Boya Times Center, Xiaoshan DistrictHANGZHOU 311200ChinaCHN
- Phone+86 57 163722229
- Fax+86 57 163715400
- Websitehttp://www.hztmyy.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hunan Nucien Pharmaceutical Co Ltd | 119.87m | -353.70m | 2.33bn | 360.00 | -- | 2.69 | -- | 19.41 | -1.28 | -1.28 | 0.4362 | 3.16 | 0.0998 | 1.41 | 0.4888 | -- | -32.50 | -5.94 | -36.98 | -8.19 | 32.41 | 83.51 | -325.67 | -15.02 | 2.29 | -139.49 | 0.1562 | -- | -64.64 | -23.64 | -9,613.65 | -- | 35.48 | -- |
| Shaanxi Kanghui Pharmaceutical Co Ltd | 513.23m | -183.84m | 2.40bn | 906.00 | -- | 3.31 | -- | 4.67 | -1.84 | -1.84 | 5.14 | 7.26 | 0.2636 | 1.93 | 2.53 | 566,479.70 | -11.36 | -1.99 | -18.19 | -2.69 | 24.46 | 36.16 | -43.08 | -6.59 | 0.5483 | -2.10 | 0.4726 | -- | -16.54 | 5.42 | -242.62 | -- | -10.54 | -- |
| Jiangsu gdk Biotechnology Co Ltd | 116.56m | -126.51m | 2.43bn | 452.00 | -- | 2.04 | -- | 20.82 | -1.03 | -1.03 | 0.9461 | 9.67 | 0.0775 | 0.7322 | 1.14 | 257,878.40 | -8.42 | 1.65 | -9.84 | 2.14 | 60.80 | 73.17 | -108.54 | 7.56 | 1.83 | -- | 0.0465 | 53.80 | -39.96 | 3.77 | -31.71 | -- | 12.74 | -- |
| Hangzhou Tianmushan Phrmtcl ntrprs C Ltd | 251.56m | 33.15m | 2.49bn | 362.00 | 75.00 | 37.34 | -- | 9.89 | 0.2723 | 0.2723 | 2.07 | 0.5468 | 0.632 | 2.97 | 2.32 | 694,905.80 | 8.32 | -8.84 | 27.42 | -25.80 | 47.93 | 32.17 | 13.17 | -21.83 | 0.655 | 9.23 | 0.648 | -- | 78.44 | -6.06 | 139.83 | -21.36 | -26.32 | -- |
| Zhejiang East Asia Pharmaceutical Co Ltd | 831.56m | -218.24m | 2.49bn | 1.75k | -- | 1.37 | -- | 3.00 | -1.97 | -1.97 | 7.34 | 15.80 | 0.2409 | 0.8634 | 5.60 | 475,447.80 | -6.33 | 2.47 | -8.09 | 3.12 | 25.78 | 24.66 | -26.25 | 5.78 | 0.7513 | -411.46 | 0.3533 | 42.92 | -11.66 | 3.93 | -183.02 | -- | 29.64 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 902.48m | -369.56m | 2.68bn | 2.10k | -- | 3.89 | -- | 2.97 | -0.9236 | -0.9236 | 2.26 | 1.72 | 0.3055 | 1.74 | 1.60 | 429,141.60 | -12.36 | 0.2178 | -22.13 | 0.3739 | 31.53 | 54.80 | -40.47 | 0.3213 | 0.5566 | -6.97 | 0.6414 | 700.10 | -21.26 | 1.60 | -2,629.23 | -- | 21.75 | -- |
| Zhejiang Shapuaisi Pharmaceutical Co Ltd | 475.19m | -65.05m | 2.76bn | 1.33k | -- | 1.71 | -- | 5.81 | -0.1796 | -0.1796 | 1.27 | 4.31 | 0.2236 | 2.35 | 14.31 | 357,822.00 | -3.08 | -2.12 | -3.66 | -2.49 | 50.11 | 55.38 | -13.78 | -7.33 | 0.8289 | -0.9506 | 0.1587 | -- | -24.96 | -1.27 | -585.85 | -- | 44.50 | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 256.00k | 0.21% |
| JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2025 | 2.90k | 0.00% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2025 | 2.40k | 0.00% |
